Generex Biotechnology (GNBT) Stock Price, News & Analysis

Company Overview

Generex Biotechnology Corp. is a development-stage biopharmaceutical company focused on the research and commercialization of innovative drug delivery technologies. The company’s proprietary RapidMist™ platform is designed to administer peptides, proteins and small molecules via the buccal, sublingual and pulmonary routes, offering a needle-free alternative to traditional injections. Generex’s lead product candidate, Oral‐lyn™, is an inhalable insulin formulation intended to provide fast-acting glycemic control for patients with diabetes.

In addition to its insulin delivery program, Generex is exploring the potential of RapidMist™ for the administration of other therapeutic agents, including vaccines and monoclonal antibodies. The platform leverages proprietary aerosolization and formulation methods to enhance bioavailability and patient compliance, while reducing the risk of needle-related injuries. The company has engaged in collaboration agreements and licensing discussions to expand the application of RapidMist™ across multiple therapeutic areas.

Generex conducts its research and development activities through its U.S. headquarters, while pursuing manufacturing and distribution partnerships in North America, Europe and select Asian markets. The company has obtained key patents covering its delivery technologies and maintains an active pipeline of product candidates at various stages of preclinical and early clinical evaluation. Generex is overseen by a board of directors and scientific advisory team with expertise in drug development, regulatory affairs and pharmaceutical commercialization.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 60,924 shs
• Market Capitalization: $73 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNBT Stock Analysis - Frequently Asked Questions

How do I buy shares of Generex Biotechnology?

Shares of GNBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Generex Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Generex Biotechnology investors own include SELLAS Life Sciences Group (SLS), (UNISQ) (UNISQ), Amgen (AMGN), VBI Vaccines (VBIV), Novavax (NVAX), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

• Today: 10/25/2025
• Fiscal Year End: 7/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GNBT
• CIK: 1059784
• Web: www.generex.com
• Phone: (416) 364-2551
• Fax: 64-7547-7104
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.66 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 122,058,000
• Free Float: 79,094,000
• Market Cap: $73 thousand
• Optionable: Not Optionable
• Beta: -0.07